Bozhi Yanxin Completes New RMB 100 Million Financing Round and Launches Business Restructuring Plan

Shanghai Bozhi Yanxin Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Bozhi Yanxin”) announced today the completion of a new round of equity financing amounting to hundreds of millions of yuan, led by Shanghai Guoxin Investment And Development Co.,Ltd. (hereinafter referred to as “Guoxin Investment”). Leveraging Bozhi Yanxin’s prominent advantages in the field of drug delivery technology, and to maintain the company’s leading position in Novel Drug Delivery Systems (NDDS),The proceeds from this financing round will be primarily allocated to the research and development of improved new drugs, advancing the clinical development and commercialization of multiple drug candidates, including BCM335, BCM331, BCM291, BCM332, BCM345, and BCM347. It is expected that by the end of 2023, the company’s most advanced improved new drug will simultaneously submit New Drug Application (NDA) filings in both China and the United States.

BociMed, established in 2012, is a high-tech pharmaceutical company dedicated to the development of innovative drugs and leading-edge therapies. Its R&D pipeline primarily focuses on therapeutic areas including central nervous system (CNS) disorders, oncology, ophthalmology, and respiratory diseases. BociMed also provides integrated small-molecule CRO/CDMO services to clients, covering upstream small-molecule synthesis and chemistry, manufacturing, and controls (CMC) services, diverse drug delivery technology services (formulation services), and downstream clinical trial services.

Bozhi Yanxin has deeply developed and established a diversified drug delivery technology platform. Over the past decade, the company has accumulated extensive technical expertise and international talent, forged partnerships with numerous leading industry clients, achieved industrialization of various formulation technologies, and submitted filings or obtained approvals for dozens of products. The company has formed specialized drug delivery technology platforms in oral administration (modified-release formulations, fixed-dose combinations, poorly soluble drug formulations, orally disintegrating films), injectable administration (RTD/RTU, microcrystalline long-acting injectables, liposomes, micelles, fat emulsions), pulmonary administration (MDIs, inhalation solutions), transdermal administration (films, ointments, creams), ocular administration (eye drops, emulsions, micelles, nanocrystals), and mucosal administration (nasal sprays, sustained-release gels). Meanwhile, it has made in-depth technological layouts in fields such as RNA delivery technologies (exosomes, liposomes). Bozhi Yanxin’s integrated CRO/CDMO service segment has been listed among the “Top 20 Industrial CROs/CDMOs” by Menet.com twice, ranked among the “Top 50 CROs/CDMOs” by the All-China Federation of Industry and Commerce six times, and frequently included in innovative technology lists selected by various professional journals and technical institutions. In 2022, the company was approved as a Postdoctoral Innovation Practice Base. To date, the company has filed nearly 170 invention patents (including 30 PCT applications), with 52 invention patents and 11 utility model patents granted.

Currently, this round of financing has been completed. BociMed is implementing a business restructuring plan. Upon completion of the restructuring, the parent company will focus on the development of innovative drugs and novel therapies in the fields of central nervous system (CNS) disorders, oncology, ophthalmology, and respiratory diseases.Continue to advance the development and commercialization of more than 20 new drugs, including BCM335, BCM331, BCM291, BCM332, BCM345, and BCM347. Among these, Investigational New Drug (IND) applications have been submitted for nine improved new drugs, and three have completed clinical trial enrollment. The improved new drug with the most advanced progress is expected to simultaneously submit New Drug Application (NDA) filings to regulatory authorities in China and the United States by the end of 2023.

Following the restructuring, the subsidiary Shanghai Bozhi Yanxin Pharmaceutical Research Co., Ltd. will continue to build upon the deep expertise and brand reputation of “Bozhi Yanxin” in the CRO/CDMO sector, focusing on integrated CRO/CDMO services. Over the past decade, Bozhi Yanxin has successfully delivered numerous contracts with compliance and speed, earning a strong reputation among clients. The restructured “Bozhi Yanxin” will comprise the Shanghai Zhangjiang Formulation Service Center, the Shanghai Lingang Synthesis and Analytical Testing Service Center, the Chengdu Runze Medical Clinical Trial and Biostatistics Service Center, and the Taizhou Bozhi Yanxin Production Service Center (currently under rapid construction). Upholding the philosophy of “customer-centricity, innovation-driven growth, and quality as the cornerstone,” Bozhi Yanxin aims to establish an international, high-quality, integrated CRO/CDMO platform to better serve its clients and ensure sustained, steady development.

About BociMed

BociMed, established in 2012, is a platform enterprise specializing in diverse drug delivery technologies. BociMed emphasizes talent and technological accumulation, boasting an international R&D team of over 300 highly qualified professionals, more than 400 SOP/SMP and procedural documents, R&D experience in over 200 pharmaceutical projects, and extensive expertise in international regulatory registration. The company has implemented LIMS and eCTD systems. BociMed possesses a comprehensive small-molecule drug delivery technology platform that has achieved industrialization, and has also made in-depth strategic investments in non-viral RNA delivery technologies, such as exosomes and liposomes.

About Guoxin Investment

Shanghai Guoxin Investment And Development Co.,Ltd. was established in 2000 with a registered capital of RMB 4 billion, and is a wholly-owned subsidiary of Shanghai State-owned Asset Management Co., Ltd. With years of experience in equity investment, Guoxin Investment has developed strong capabilities in project screening, investment, and management, and has successfully invested in numerous well-known domestic biopharmaceutical and medical device companies. Adhering to its business philosophy of “Discovering Value, Creating Value, and Growing Together with Outstanding Enterprises,” Guoxin Investment will continue to play a significant role in implementing Shanghai International Group’s strategic mandate to empower the real economy with financial capital and support the development of Shanghai as a global science and technology innovation hub.